Product
Comirnaty
Aliases
Comirnaty Omicron XBB1.5
17 clinical trials
11 indications
Indication
COVID-19Indication
VaccinesIndication
InfluenzaIndication
HumanIndication
COVID-19 vaccineIndication
CancerIndication
VaccinationIndication
Systemic Allergic ReactionIndication
Diabetes MellitusIndication
Type 1Indication
Adverse Reaction to ImmunizationClinical trial
Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to Assess the Safety and Immunogenicity of a Booster Vaccination With an Adapted Recombinant Protein RBD Fusion Homodimer Candidate Against SARS-CoV-2, in Adults Vaccinated Against COVID-19Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 VaccineStatus: Withdrawn, Estimated PCD: 2022-07-01
Clinical trial
A Multi-center, Observer-blind, Randomized, Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019), Administered as a Booster Dose to Adults, Who Previously Received Primary Series of a COVID-19 VaccineStatus: Completed, Estimated PCD: 2023-06-06
Clinical trial
Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts-Randomized, Double-blind, Active Controlled and Open-label, Single-armStatus: Completed, Estimated PCD: 2023-03-15
Clinical trial
A Phase IIb, Double-Blind, Randomized, Active Controlled, Multi-center, Non-inferiority Trial to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19Status: Completed, Estimated PCD: 2022-10-01
Clinical trial
Investigating Uptake and Subsequent Health Outcomes Associated With Pfizer-BioNTech Bivalent COVID-19/Influenza Vaccine Concomitant Administration Using a Claims-based Real-world Data Source in the USStatus: Completed, Estimated PCD: 2023-05-12
Clinical trial
Randomized, Blinded, Positive Control Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Aged 18-59 YearsStatus: Not yet recruiting, Estimated PCD: 2023-02-01
Clinical trial
A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the Preventive COVID-19 Vaccine AdCLD-CoV19-1 OMI Administered as a Booster to Adults Aged 19 Years Old and AboveStatus: Not yet recruiting, Estimated PCD: 2024-05-01
Clinical trial
Phase IIb, Randomized, Double-blind, Non-inferior, Multicenter Study to Evaluate the Safety and Immunogenicity of the Self-replicating Nanoparticle Carrier Replicon RNA Carrier (repRNA) Vaccine in Adults 18 to 65 Years of AgeStatus: Not yet recruiting, Estimated PCD: 2023-03-01
Clinical trial
A Randomized, Double-blind, and Positive-controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥18 Years Previously Vaccinated With Either Inactivated or mRNA COVID-19 Vaccine or Previously Diagnosed With COVID-19Status: Active (not recruiting), Estimated PCD: 2022-10-28
Clinical trial
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2Status: Terminated, Estimated PCD: 2024-01-08
Clinical trial
Intradermal Administration of a COVID-19 mRNA Vaccine in ElderlyStatus: Terminated, Estimated PCD: 2024-03-21
Clinical trial
A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial DoseStatus: Completed, Estimated PCD: 2022-06-17
Clinical trial
Anti-viral Action Against Type 1 Diabetes AutoimmunityStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter StudyStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine and a Booster Dose of Pfizer-BioNTech or Moderna mRNA VaccineStatus: Active (not recruiting), Estimated PCD: 2022-07-15
Clinical trial
Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine: A Non-inferiority Multicenter Single-blinded, Randomized TrialStatus: Active (not recruiting), Estimated PCD: 2023-07-12